Patents by Inventor Sheri Moores

Sheri Moores has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific EGFR/c-Met antibodies
    Patent number: 12247077
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: March 11, 2025
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
    Patent number: 12215161
    Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: February 4, 2025
    Assignee: Janssen Biotech, Inc.
    Inventors: Sheri Moores, Smruthi Vijayaraghavan
  • Treatment of patients having c-met exon 14 skipping mutations
    Patent number: 12215160
    Abstract: The present invention relates to treatment of subjects having a cancer that is positive for c-Met exon 14 skipping mutations.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: February 4, 2025
    Assignee: Janssen Biotech, Inc.
    Inventors: Roland Knoblauch, Sylvie Laquerre, Sheri Moores
  • Treatment of Cancers Lacking EGFR- Activating Mutations
    Publication number: 20240228634
    Abstract: The present invention relates to treatment of subjects having cancers with tumors lacking an at least one EGFR-activating mutation.
    Type: Application
    Filed: March 22, 2024
    Publication date: July 11, 2024
    Inventors: Benjamin Henley, Sheri Moores
  • COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND THIRD GENERATION EGFR TYROSINE KINASE INHIBITORS
    Publication number: 20240199748
    Abstract: The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors.
    Type: Application
    Filed: November 15, 2023
    Publication date: June 20, 2024
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Sylvie LAQUERRE, Matthew LORENZI, Sheri MOORES
  • Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer
    Publication number: 20240067736
    Abstract: The present disclosure provides methods of treating liver cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.
    Type: Application
    Filed: May 5, 2023
    Publication date: February 29, 2024
    Inventor: Sheri Moores
  • Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
    Patent number: 11879013
    Abstract: The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: January 23, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Sylvie Laquerre, Matthew Lorenzi, Sheri Moores
  • COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES
    Publication number: 20230130600
    Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
    Type: Application
    Filed: August 3, 2022
    Publication date: April 27, 2023
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Sheri MOORES, Smruthi VIJAYARAGHAVAN
  • Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
    Patent number: 11459391
    Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: October 4, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Sheri Moores, Smruthi Vijayaraghavan
  • Treatment of Cancers Lacking EGFR- Activating Mutations
    Publication number: 20220298248
    Abstract: The present invention relates to treatment of subjects having cancers with tumors lacking an at least one EGFR-activating mutation.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 22, 2022
    Inventors: Benjamin Henley, Sheri Moores
  • Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
    Publication number: 20220064306
    Abstract: The present invention relates to treatment of subjects having EGFR exon 20 insertion and other uncommon EGFR mutations.
    Type: Application
    Filed: August 25, 2021
    Publication date: March 3, 2022
    Inventors: Roland Knoblauch, Sheri Moores
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20210395373
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 23, 2021
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Treatment of Patients Having c-Met Exon 14 Skipping Mutations
    Publication number: 20210253717
    Abstract: The present invention relates to treatment of subjects having a cancer that is positive for c-Met exon 14 skipping mutations.
    Type: Application
    Filed: February 12, 2021
    Publication date: August 19, 2021
    Inventors: Roland Knoblauch, Sylvie Laquerre, Sheri Moores
  • EGFR and C-Met Fibronectin Type III Domain Binding Molecules
    Publication number: 20210206825
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 8, 2021
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • EGFR and c-Met fibronectin type III domain binding molecules
    Patent number: 10954284
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Combination Therapies With Bispecific Anti-EGFR/c-Met Antibodies and Third Generation EGFR Tyrosine Kinase Inhibitors
    Publication number: 20210017285
    Abstract: The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors.
    Type: Application
    Filed: May 14, 2020
    Publication date: January 21, 2021
    Inventors: Sylvie Laquerre, Matthew Lorenzi, Sheri Moores
  • CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
    Publication number: 20200325210
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Application
    Filed: April 6, 2020
    Publication date: October 15, 2020
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Combination Therapies and Patient Stratification with Bispecific Anti-EGFR/c-Met Antibodies
    Publication number: 20200270351
    Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
    Type: Application
    Filed: February 24, 2020
    Publication date: August 27, 2020
    Inventors: Sheri Moores, Smruthi Vijayaraghavan
  • Cysteine engineered fibronectin type III domain binding molecules
    Patent number: 10662235
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 26, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Alastair King, Steven Jacobs, Shalom Goldberg, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20200087407
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman